Citi lowered the firm’s price target on Neurocrine to $140 from $141 and keeps a Neutral rating on the shares post the Q4 report. Ingrezza revenues for fiscal 2024 came in at the upper end of guidance but slightly below consensus, and the fiscal 2024 guidance portends more modest year-over-year growth, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
- NBIX Earnings this Week: How Will it Perform?
- Neurocrine price target raised to $150 from $145 at Barclays
- Neurocrine director Lyons, Chief Medical Officer Roberts sell $1.3M in stock
- Neurocrine price target raised to $145 from $125 at Barclays
